Furthermore, the ability of pGSN to identify young MD patients warrants further research to confirm its potential utility in pediatric patient series, where GDF15 and FGF21 have been shown to be less relevant in differentiating multisystemic mitochondrial disorders from other metabolic diseases [30]. This evidence concerns the gene GDF15 and metabolic disease.